Concepedia

Author

Olivier J. van Not

Zuyderland Medisch CentrumORCID

Also Known As

O. J. Van Not, O. J. van Not, O.J. van Not, Olivier J van Not, Olivier J. Van Not, Olivier J. van Not, Olivier van Not

31

Publications

344

Citations

9

H-Index

10

Concepts

All Affiliations

Zuyderland Medisch CentrumMedisch Centrum LeeuwardenUniversity Medical Center UtrechtRadboud University NijmegenCancer Center Amsterdam
OJ

About

Olivier J. van Not is an author at Zuyderland Medisch Centrum specializing in cancer therapeutics, radiation oncology, and tumor immunity.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

13

2

Immunology

1

1

13

3

Surgical Oncology

1

1

13

4

Cancer Therapeutics

1

1

13

5

Immunotherapy

1

1

13

Olivier J. van Not

×

9

Publications

300

Citations

9

H-Index

YearCitations

Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma

Olivier J. van Not, Rik J. Verheijden, Alfonsus Johannes Maria van den Eertwegh,

JAMA Oncology

2022

99

Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study

Olivier J. van Not, Melissa M. de Meza, Alfons J.M. van den Eertwegh,

European Journal of Cancer

2022

56

Adjuvant treatment for melanoma in clinical practice – Trial versus reality

Melissa M. de Meza, Rawa K. Ismail, Daan Jan Willem Rauwerdink,

European Journal of Cancer

2021

32

Long-Term Survival in Patients With Advanced Melanoma

Olivier J. van Not, Alfons J.M. van den Eertwegh, Manja Bloem,

JAMA Network Open

2024

27

The unfavorable effects of <scp>COVID</scp>‐19 on Dutch advanced melanoma care

Olivier J. van Not, Jesper van Breeschoten, Alfonsus Johannes Maria van den Eertwegh,

International Journal of Cancer

2021

22

Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021

Olivier J. van Not, Alfons J.M. van den Eertwegh, John B.A.G. Haanen,

EClinicalMedicine

2024

20

<i>BRAF</i> and <i>NRAS</i> Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma

Olivier J. van Not, Willeke A.M. Blokx, Alfons J.M. van den Eertwegh,

JCO Precision Oncology

2022

18

Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis

Melissa M. de Meza, Willeke A.M. Blokx, Johannes J. Bonenkamp,

Cancers

2023

13

BRAF/MEK inhibitor rechallenge in advanced melanoma patients

Olivier J. van Not, Alfons J.M. van den Eertwegh, John B.A.G. Haanen,

Cancer

2024

13

Page 1